Polycystic Kidney Disease Pipeline Market Reviews of Therapeutics by Worldwide Companies, Universities and Research Institutes, H1 2017

Offers from 10th May 2017 to 2nd June 2017
• All reports priced >=1,000 – 20% Discount – Single User; 25% Discount – Global Site License.
• Buy 2 Reports Get 1 Report Free
Market Research on Polycystic Kidney Disease Pipeline - Therapeutics Development in H1 2017 report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, route of administration and molecule type.
Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.
Complete Report on Polycystic Kidney Disease Pipeline Market Reviews is Available at http://www.reportsnreports.com/reports/992902-polycystic-kidney-disease-pipeline-review-h1-2017.html .

The Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Purchase the Report @ http://www.reportsnreports.com/purchase.aspx?name=992902.

Companies involved in Therapeutics Development
3SBio Inc
Angion Biomedica Corp
Aptevo Therapeutics Inc
Conatus Pharmaceuticals Inc
Discovery Biomed Inc
Endocyte Inc
IC-MedTech Inc
Ipsen SA
Kadmon Corp LLC
ManRos Therapeutics
Metabolic Solutions Development Company LLC
Mironid Ltd
NovaTarg Therapeutics Inc
Otsuka Holdings Co Ltd
Q BioMed Inc
Regulus Therapeutics Inc
XORTX Pharma Corp
Polycystic Kidney Disease - Drug Profiles
ANG-3070, CIM-2, CR-8, DBM-43H11, DJ-5, Drug for Cystic Kidney Disease - Drug Profile, Product Description, Mechanism Of Action, R&D Progress,EC-0371 - Drug Profile, Product Description, Mechanism Of Action, R&D Progress,IDN-8050 - Drug Profile, Product Description, Mechanism Of Action, R&D Progress,JP-153 - Drug Profile, Product Description, Mechanism Of Action, R&D Progress, lanreotide acetate - Drug Profile, Product Description, Mechanism Of Action, R&D Progress, menadione sodium bisulfite - Drug Profile, Product Description, Mechanism Of Action, R&D Progress,MSDC-0160 - Drug Profile, Product Description, Mechanism Of Action, R&D Progress, oxypurinol - Drug Profile, Product Description, Mechanism Of Action, R&D Progress, pyrimethamine - Drug Profile, Product Description, Mechanism Of Action, R&D Progress,RGLS-4326 - Drug Profile
Inquire for Discount http://www.reportsnreports.com/contacts/discount.aspx?name=992902 .
The Report on Polycystic Kidney Disease is provided with scope mentioned in the following
• The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)
Featured News & Press Releases
1. Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan
2. Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD
3. Dec 06, 2016: Regulus Announces Update on RGLS4326
4. Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016
5. Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease
6. Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015
7. May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
8. Apr 14, 2015: Discovery BioMed is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases
9. Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease
10. Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease
Browse All Reports on Pharmaceuticals Market Research Reports.
Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected] with Global Construction Industry in subject line and your contact details.
About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.